Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan S Berek

Showing results (21-30 of 137) with videos related to

Pageof 14
Sort By:
Current Problems in Cancer|February 8, 2017
Immunotherapy in ovarian cancerVenkatesh Krishnan, Jonathan S Berek, Oliver Dorigo
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|September 5, 2025
Cancer of the ovary, fallopian tube, and peritoneum: 2025 updateMalte Renz, Michael Friedlander, Jonathan S Berek
Obstetrics and Gynecology|July 26, 2018
Occult Gynecologic Cancer in Women Undergoing Hysterectomy or Myomectomy for Benign IndicationsEva Chalas, Daniel Clarke-Pearson, Jonathan S Berek
JCO Global Oncology|March 4, 2022
Management and Care of Patients With Invasive Cervical Cancer: ASCO Resource-Stratified Guideline Rapid Recommendation UpdateLinus T Chuang, Sarah Temin, Jonathan S Berek, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 28, 2009
Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experienceMaurie Markman, Mark Brady, Alan Hutson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2003
Biologic and immunologic therapies for ovarian cancerJonathan S Berek, Birgit C Schultes, Christopher F Nicodemus
Current Opinion in Obstetrics & Gynecology|December 5, 2020
Cell-based immunotherapy in gynecologic malignanciesKalika Kamat, Venkatesh Krishnan, Jonathan S Berek, et al.
Gynecologic Oncology|February 15, 2003
Specific keynote: immunological therapy for ovarian cancerJonathan S Berek, Oliver Dorigo, Brigit Schultes, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2008
CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancerJonathan S Berek, Peyton T Taylor, Christopher F Nicodemus
Journal for Immunotherapy of Cancer|March 26, 2015
Immunotherapeutic approaches to ovarian cancer treatmentCariad Chester, Oliver Dorigo, Jonathan S Berek, et al.
Pageof 14

Showing results (21-30 of 137) with videos related to

Sort By:
Pageof 14
Current Problems in Cancer|February 8, 2017
Immunotherapy in ovarian cancerVenkatesh Krishnan, Jonathan S Berek, Oliver Dorigo
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|September 5, 2025
Cancer of the ovary, fallopian tube, and peritoneum: 2025 updateMalte Renz, Michael Friedlander, Jonathan S Berek
Obstetrics and Gynecology|July 26, 2018
Occult Gynecologic Cancer in Women Undergoing Hysterectomy or Myomectomy for Benign IndicationsEva Chalas, Daniel Clarke-Pearson, Jonathan S Berek
JCO Global Oncology|March 4, 2022
Management and Care of Patients With Invasive Cervical Cancer: ASCO Resource-Stratified Guideline Rapid Recommendation UpdateLinus T Chuang, Sarah Temin, Jonathan S Berek, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 28, 2009
Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experienceMaurie Markman, Mark Brady, Alan Hutson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2003
Biologic and immunologic therapies for ovarian cancerJonathan S Berek, Birgit C Schultes, Christopher F Nicodemus
Current Opinion in Obstetrics & Gynecology|December 5, 2020
Cell-based immunotherapy in gynecologic malignanciesKalika Kamat, Venkatesh Krishnan, Jonathan S Berek, et al.
Gynecologic Oncology|February 15, 2003
Specific keynote: immunological therapy for ovarian cancerJonathan S Berek, Oliver Dorigo, Brigit Schultes, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2008
CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancerJonathan S Berek, Peyton T Taylor, Christopher F Nicodemus
Journal for Immunotherapy of Cancer|March 26, 2015
Immunotherapeutic approaches to ovarian cancer treatmentCariad Chester, Oliver Dorigo, Jonathan S Berek, et al.
Pageof 14